Long-term INDIGO data show vorasidenib extends progression-free survival, delays next treatment, and cuts seizures in post-surgery IDH-mutant glioma.
Timothy F. Cloughesy, MD
Advertisement
Timothy Cloughesy, MD, is the director of the neuro-oncology program at the UCLA Brain Research Institute.
Articles by Timothy F. Cloughesy, MD
Timothy F. Cloughesy, MD, director of UCLA’s neuro-oncology program and distinguished professor in neurology, discusses the mechanism of action of vorasidenib.
Timothy F. Cloughesy, MD, discusses the impact and significance of the FDA’s approval of vorasidenib, a first-in-class option for the treatment of patients with IDH-mutant gliomas.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
Zipalertinib Combo Meets PFS End Point in First-Line EGFR Exon 20+ NSCLC
3
FDA Grants Breakthrough Device Designation to Blood-Based Lung Cancer Screening
4
Talquetamab Shows Durable Responses in R/R MM at 3-Year Follow-Up
5